Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

被引：4

作者：

Xu, R-H. ^{[1
]}

Oh, D-Y. ^{[2
]}

Kato, K. ^{[3
]}

Arkenau, T. ^{[4
]}

Tabernero, J. ^{[5
]}

Cruz-Correa, M. ^{[6
]}

Zimina, A. ^{[7
]}

Bai, Y. ^{[8
]}

Shi, J. ^{[9
]}

Lee, K-W. ^{[10
]}

Hirano, H.

Spigel, D. R. ^{[11
]}

Wyrwicz, L. S. ^{[12
]}

Cid, R. A. Pazo ^{[13
]}

Li, L. ^{[14
]}

Xu, Y. ^{[15
]}

McHenry, M. B. ^{[16
]}

Yang, S. ^{[14
]}

Moehler, M. ^{[17
]}

机构：

[1] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, Canc Ctr,State Key Lab Oncol South China, Guangzhou, Peoples R China

[2] Seoul Natl Univ, Hosp Canc Res Inst, Dept Internal Med, Coll Med, Seoul, South Korea

[3] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan

[4] Sarah Cannon Res Inst, Dept Drug Dev, London, England

[5] Vall dHebron Hosp Campus & Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain

[6] Univ Puerto Rico, Sch Med, San Juan, PR USA

[7] BIH Omsk Region, Dept Oncol, Clin Oncol Dispensary, Omsk, Russia

[8] Harbin Med Univ, Dept Gastrointestinal Oncol, Canc Hosp, Harbin, Peoples R China

[9] Linyi Canc Hosp, Dept Med Oncol 2, Linyi, Shandong, Peoples R China

[10] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi Do, South Korea

[11] Tennessee Oncol, Dept Thorac Med Oncol, Nashville, TN USA

[12] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Oncol & Radiotherapy, Warsaw, Poland

[13] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain

[14] BeiGene Beijing Co Ltd, Clin Dev Clin Biomarker, Beijing, Peoples R China

[15] BeiGene Shanghai Co Ltd, Clin Dev, Shanghai, Peoples R China

[16] BeiGene USA Inc, GSDS, Cambridge, MA USA

[17] Johannes Gutenberg Univ Clin, Dept Internal Med 1, Mainz, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.081

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA80

引用

页码：S1320 / S1321

页数：2

共 50 条

[21] First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Ruihua
Guo, Weijian
Qin, Shukui
Yang, Nong
Lu, Jianwei
Shitara, Kohei
Lei, Ming
Li, Mingshun
Bao, Nicole
Chen, Tian
Liu, Tianshu
CANCER RESEARCH, 2021, 81 (13)
[22] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 291 - 291
[23] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.
Janjigian, Yelena Y.
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Bruges, Ricardo Elias
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
McCraith, Stephen
Hu, Nan
Zhang, Jennifer
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 398 - 398
[24] Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649
Shitara, Kohei
Janjigian, Yelena Y.
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Silva, Arinilda
Bragagnoli, Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Soleymani, Samira
Lei, Ming
Kondo, Kaoru
Li, Mingshun
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[25] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Qiu, Miao-Zhen
Oh, Do-Youn
Kato, Ken
Arkenau, Tobias
Tabernero, Josep
Correa, Marcia Cruz
Zimina, Anastasia, V
Bai, Yuxian
Shi, Jianhua
Lee, Keun-Wook
Wang, Jufeng
Poddubskaya, Elena
Pan, Hongming
Rha, Sun Young
Zhang, Ruixing
Hirano, Hidekazu
Spigel, David
Yamaguchi, Kensei
Chao, Yee
Wyrwicz, Lucjan
Disel, Umut
Cid, Roberto Pazo
Fornaro, Lorenzo
Evesque, Ludovic
Wang, Hongwei
Xu, Yaling
Li, Jiang
Sheng, Tao
Yang, Silu
Li, Liyun
Moehler, Markus
Xu, Rui-Hua
BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
[26] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
Moehler, Markus H.
Shitara, Kohei
Garrido, Marcelo
Salman, Pamela
Shen, Lin
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Schenker, Michael
Yanez, Patricio Eduardo
Tehfe, Mustapha
Li, Mingshun
Cullen, Dana
Memaj, Arteid
Lei, Ming
Xiao, Hong
Janjigian, Yelena Y.
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[27] Randomized, global, phase 3 study of tislelizumab (TIS) plus chemotherapy (chemo) versus placebo (PBO) plus chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.
Raymond, Eric
Hubner, Richard
Gotovkin, Evgeny
Wyrwicz, Lucjan
Van Cutsem, Eric
Jimenez-Fonseca, Paula
Pazo-Cid, Roberto
Xu, Jianming
Kato, Ken
Tao, Aiyang
Wang, Lei
Peng, Yanyan
Li, Liyun
Yoon, Harry H.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 340 - 340
[28] Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Cruz-Correa, M.
Oh, D-Y.
Kato, K.
Tabernero, J.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Spigel, D. R.
Wyrwicz, L. S.
Pazo Cid, R. A.
Cubillo Gracian, A.
Li, L.
Xu, Y.
Sheng, T.
Yang, S.
Xu, R-H.
Moehler, M.
ANNALS OF ONCOLOGY, 2024, 35 : S893 - S894
[29] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
Sullivan, Kendall
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
[30] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649
Wyrwicz, L. S.
Shitara, K.
Moehler, M.
Ajani, J. A.
Shen, L.
Garrido, M.
Gallardo Araneda, C. E.
Yamaguchi, K.
Cleary, J.
Elimova, E.
Bruges Maya, R.
Karamouzis, M. V.
Skoczylas, T.
Bragagnoli, A. C.
Liu, T.
Tehfe, M.
Feeney, K.
Wang, R.
Zhang, J.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2024, 35 : S169 - S170

← 1 2 3 4 5 →